TRELEGY Ellipta safety profile
TRELEGY Ellipta is generally well tolerated and has a comparable safety profile to that of its components. 1
The safety profile is based on three studies with 5589 patients treated with Trelegy Ellipta over 24-52 weeks. These studies were the FULFIL, IMPACT and 200812 studies. 1
Common adverse reactions (≥1/100 to <1/10): | ||||
Headache | Nasopharyngitis | Influenza | Upper respiratory tract infection | Pneumonia |
Back pain | Rhinitis | Cough | Pharyngitis | Arthralgia |
Bronchitis | Candiasis of throat and mouth | Sinusitis | Urinary Tract Infection |
Find the full list of adverse reactions in the TRELEGY Ellipta Summary of Product Characteristics.
Abbreviations
ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily
References:
- TRELEGY Ellipta SmPC, 2018 Available at www.medicines.ie [Accessed December 2018].
- Lipson DA et al. Am J Respir Crit Care Med 2017; 196:438-446.
- Lipson DA et al. N Engl J Med 2018; 378:1671-1680
TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA 1
© 2018 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners